Login / Signup

mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies.

Zhenfei XieYing-Cing LinJon M SteichenGabriel OzorowskiSven KratochvilRashmi RayJonathan L TorreAlessia LiguoriOleksandr KalyuzhniyXuesong WangJohn E WarnerStephanie R WeldonGordon A DaleKathrin H KirschUsha NairSabyasachi BabooErik GeorgesonYumiko AdachiMichael KubitzAbigail M JacksonSara T RicheyReid M VolkJeong Hyun LeeJolene K DiedrichThavaleak PrumSamantha FalconeSunny HimansuAndrea CarfiJohn Yates IiiJames C PaulsonDevin SokAndrew B WardWilliam R SchiefFacundo D Batista
Published in: Science (New York, N.Y.) (2024)
Germline-targeting (GT) HIV vaccine strategies are predicated on deriving broadly neutralizing antibodies (bnAbs) through multiple boost immunogens. However, as the recruitment of memory B cells (MBCs) to germinal centers (GCs) is inefficient and may be derailed by serum antibody-induced epitope masking, driving further B cell receptor (BCR) modification in GC-experienced B cells after boosting poses a challenge. Using humanized immunoglobulin knockin mice, we found that GT protein trimer immunogen N332-GT5 could prime inferred-germline precursors to the V3-glycan-targeted bnAb BG18 and that B cells primed by N332-GT5 were effectively boosted by either of two novel protein immunogens designed to have minimum cross-reactivity with the off-target V1-binding responses. The delivery of the prime and boost immunogens as messenger RNA lipid nanoparticles (mRNA-LNPs) generated long-lasting GCs, somatic hypermutation, and affinity maturation and may be an effective tool in HIV vaccine development.
Keyphrases